bioRxivBioengineering
HIGH-CONTENT, CELL-BY-CELL ASSESSMENT OF HER2 OVEREXPRESSION AND AMPLIFICATION FOR HETEROGENEITY DETECTION IN BREAST CANCER
H. T. Nguyen, D. Migliozzi, B. Bisig, L. de Leval, M. A. M. Gijs
Abstract
Immunohistochemistry and fluorescence in situ hybridization are the two standard methods for Human Epidermal Growth Factor Receptor 2 (HER2) assessment. However, they have severe limitations to assess quantitatively intratumoral heterogeneity (ITH) when multiple subclones of tumor cells co-exist. We develop here a high-content, quantitative analysis of breast cancer tissues based on microfluidic experimentation and image processing, to characterize both HER2 protein overexpression and HER2 gene amplification at the cell level. The technique consists of performing sequential steps on the same tissue slide: an immunofluorescence (IF) assay using a microfluidic protocol, an elution step for removing the IF staining agents, a standard FISH staining protocol, followed by automated quantitative cell-by-cell image processing. Moreover, ITH is accurately detected in both cluster and mosaic form using an analysis of spatial association and a mathematical model that allows discriminating true heterogeneity from artifacts due to the use of thin tissue sections. This study paves the way to evaluate ITH with high accuracy and content while requiring standard staining methods.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Quantification of HER2-low and ultra-low expression in breast cancer specimens by quantitative IHC and artificial intelligence
Frederik Aidt, Elad Arbel, … Anya Tsalenko·Journal of Pathology InformaticsPeer-reviewed·Aug 26, 2025
- A novel HER2 protein identification methodology in breast cancer cells using Raman spectroscopy and Raman imaging: an analytical validation study
Halina Abramczyk, Jakub Maciej Surmacki, Monika Kopeć·Journal of Medicinal ChemistryPeer-reviewed·Sep 21, 2024
- Intra-tumor heterogeneity defines treatment-resistant HER2+ breast tumors
I. H. Rye, A. Trinh, … H. G. Russnes·bioRxiv·Apr 18, 2018
- Grading HER2 at the nanoscale in clinical tissue
Lauren Toms, Hervé Barjat, … Emily Offer·bioRxiv·Jan 14, 2026
- Automated detection of the HER2 gene amplification status in Fluorescence in situ hybridization images for the diagnostics of cancer tissues
F. Zakrzewski, W. de Back, … P. Hoenscheid·bioRxiv·May 23, 2019
- In situ single-cell analysis of canonical breast cancer biomarkers: phenotypic heterogeneity and implications on response to HER2 targeting agents.
G. Serna, E. Garcia, … P. G. Nuciforo·bioRxiv·Sep 21, 2022